Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 8/20 | 0.69 |
| ▸ | OXTR | P30559 | 4/20 | 0.69 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.49 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428848 | 1.00 | AVPR1A (0.69) | AVPR1AOXTRAVPR2SLC6A7GHSR | |
| SCHEMBL21255738 | 0.87 | AVPR1A (0.68) | AVPR1AOXTRAVPR2SLC6A7GHSR | |
| SCHEMBL4417850 | 0.86 | OXTR (0.51) | AVPR1AOXTRSLC6A7HCRTR1HCRTR2 | |
| SCHEMBL301777 | 0.86 | OXTR (0.51) | AVPR1AOXTRSLC6A7HCRTR1HCRTR2 | |
| Oxyquinoline SCHEMBL25424783 | 0.85 | AVPR1A (0.53) | AVPR1AOXTRAVPR2SLC6A7HCRTR1 | |
| SCHEMBL16550630 | 0.85 | AVPR1A (0.78) | AVPR1AOXTRAVPR2SLC6A7GHSR | |
| SCHEMBL16550628 | 0.85 | AVPR1A (0.78) | AVPR1AOXTRAVPR2SLC6A7GHSR | |
| SCHEMBL29642210 | 0.85 | AVPR1A (0.78) | AVPR1AOXTRAVPR2SLC6A7GHSR | |
| SCHEMBL29449383 | 0.85 | AVPR1A (0.78) | AVPR1AOXTRAVPR2SLC6A7GHSR | |
| SCHEMBL16559069 | 0.85 | AVPR1A (0.78) | AVPR1AOXTRAVPR2SLC6A7GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252037-B1 | PROCESS FOR THE PREPARATION OF (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2´-METHYL-1,1´-BIPHENYL-4-YL)CARBONYL)PYRROLIDIN-3-ONE O-METHYLOXIME | ObsEva SA (CH) | 2022-03-09 | — | — | EP | claimed |
| EP-1532109-B1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK SERONO SA (CH) | 2009-09-09 | — | — | EP | claimed |
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2024-07-11 | — | — | US | disclosed |
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2024-07-11 | — | — | US | disclosed |
| US-20230226021-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230097933-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2023-03-30 | — | — | US | disclosed |
| US-20230097933-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2023-03-30 | — | — | US | disclosed |
| EP-4129979-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ObsEva S.A. (CH) | 2023-02-08 | — | — | EP | disclosed |
| EP-4129979-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ObsEva S.A. (CH) | 2023-02-08 | — | — | EP | disclosed |
| EP-4103750-A1 | BIOMARKERS FOR OXYTOCIN RECEPTOR ANTAGONIST THERAPY | ObsEva S.A. (CH) | 2022-12-21 | — | — | EP | disclosed |
| US-11419851-B2 | Oral formulations of pyrrolidine derivatives | ObsEva S.A. (CH) | 2022-08-23 | — | — | US | disclosed |
| WO-2016000920-A1 | CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME USEFUL IN METHODS OF TREATING CONDITIONS RELATED TO THE OT-R ACTIVITY | ObsEva SA (CH) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016000920-A1 | CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME USEFUL IN METHODS OF TREATING CONDITIONS RELATED TO THE OT-R ACTIVITY | ObsEva SA (CH) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016000920-A1 | CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME USEFUL IN METHODS OF TREATING CONDITIONS RELATED TO THE OT-R ACTIVITY | ObsEva SA (CH) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002160-A1 | CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME, AND METHODS OF USING THE SAME | ReproNovo SA (CH) | 2016-01-07 | — | — | US | disclosed |
| WO-2015091365-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ObsEva S.A. (CH) | 2015-06-25 | — | — | WO | disclosed |
| EP-2886107-A1 | Oral formulations of pyrrolydine derivatives | ObsEva S.A. (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150073032-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2015-03-12 | — | — | US | disclosed |
| EP-2845850-A1 | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists | ObsEva S.A. (CH) | 2015-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073032-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | AVPR1A 2/4885OXTR 1/4885AVPR2 3/4885 |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | AVPR1A 2299/4885OXTR 76/4885AVPR2 1956/4885 |
| US-20230097933-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | AVPR1A 2/4885OXTR 1/4885AVPR2 3/4885 |
| US-11419851-B2 | Oral formulations of pyrrolidine derivatives | KDM5A, KDM5C, PGF | AVPR1A 2409/4885OXTR 70/4885AVPR2 2053/4885 |
| US-20160002160-A1 | CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME, AND METHODS OF USING THE SAME | OXTR, OXER1, ZP1 | AVPR1A 1692/4885OXTR 1/4885AVPR2 1815/4885 |
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | AVPR1A, OXTR, AVPR2 | AVPR1A 1/4885OXTR 2/4885AVPR2 3/4885 |
| US-20230226021-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | AVPR1A 2299/4885OXTR 76/4885AVPR2 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.